BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Klein AP. Identifying people at a high risk of developing pancreatic cancer. Nat Rev Cancer. 2013;13:66-74. [PMID: 23222481 DOI: 10.1038/nrc3420] [Cited by in Crossref: 90] [Cited by in F6Publishing: 82] [Article Influence: 10.0] [Reference Citation Analysis]
Number Citing Articles
1 Dwarte T, McKay S, Johns A, Tucker K, Spigelman AD, Williams D, Stoita A. Genetic counselling and personalised risk assessment in the Australian pancreatic cancer screening program. Hered Cancer Clin Pract 2019;17:30. [PMID: 31666883 DOI: 10.1186/s13053-019-0129-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
2 Smith AL, Wong C, Cuggia A, Borgida A, Holter S, Hall A, Connor AA, Bascuñana C, Asselah J, Bouganim N, Poulin V, Jolivet J, Vafiadis P, Le P, Martel G, Lemay F, Beaudoin A, Rafatzand K, Chaudhury P, Barkun J, Metrakos P, Marcus V, Omeroglu A, Chong G, Akbari MR, Foulkes WD, Gallinger S, Zogopoulos G. Reflex Testing for Germline BRCA1 , BRCA2 , PALB2 , and ATM Mutations in Pancreatic Cancer: Mutation Prevalence and Clinical Outcomes From Two Canadian Research Registries. JCO Precision Oncology 2018. [DOI: 10.1200/po.17.00098] [Cited by in Crossref: 8] [Cited by in F6Publishing: 1] [Article Influence: 2.7] [Reference Citation Analysis]
3 Yang XR, Rotunno M, Xiao Y, Ingvar C, Helgadottir H, Pastorino L, van Doorn R, Bennett H, Graham C, Sampson JN, Malasky M, Vogt A, Zhu B, Bianchi-Scarra G, Bruno W, Queirolo P, Fornarini G, Hansson J, Tuominen R, Burdett L, Hicks B, Hutchinson A, Jones K, Yeager M, Chanock SJ, Landi MT, Höiom V, Olsson H, Gruis N, Ghiorzo P, Tucker MA, Goldstein AM. Multiple rare variants in high-risk pancreatic cancer-related genes may increase risk for pancreatic cancer in a subset of patients with and without germline CDKN2A mutations. Hum Genet 2016;135:1241-9. [PMID: 27449771 DOI: 10.1007/s00439-016-1715-1] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 3.4] [Reference Citation Analysis]
4 Li J, Jin Q, Huang F, Tang Z, Huang J. Effects of Rab27A and Rab27B on Invasion, Proliferation, Apoptosis, and Chemoresistance in Human Pancreatic Cancer Cells. Pancreas 2017;46:1173-9. [DOI: 10.1097/mpa.0000000000000910] [Cited by in Crossref: 21] [Cited by in F6Publishing: 10] [Article Influence: 5.3] [Reference Citation Analysis]
5 Harada A, Matsumoto S, Yasumizu Y, Shojima K, Akama T, Eguchi H, Kikuchi A. Localization of KRAS downstream target ARL4C to invasive pseudopods accelerates pancreatic cancer cell invasion. Elife 2021;10:e66721. [PMID: 34590580 DOI: 10.7554/eLife.66721] [Reference Citation Analysis]
6 Chen C, Wang W, Wang W, Wang Y, Yu Z, Li Y. Locally advanced pancreatic carcinoma with jaundice: the benefit of a sequential treatment with stenting followed by CT-guided 125I seeds implantation. Eur Radiol 2021;31:6500-10. [PMID: 33630162 DOI: 10.1007/s00330-021-07764-6] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Alsubai J, Matters GL, McGovern CO, Liao J, Gilius EL, Smith JP. Germline Mutation of the CCK Receptor: A Novel Biomarker for Pancreas Cancer. Clin Transl Gastroenterol 2016;7:e134. [PMID: 26741064 DOI: 10.1038/ctg.2015.61] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
8 Güngör C, Hofmann BT, Wolters-Eisfeld G, Bockhorn M. Pancreatic cancer. Br J Pharmacol. 2014;171:849-858. [PMID: 24024905 DOI: 10.1111/bph.12401] [Cited by in Crossref: 39] [Cited by in F6Publishing: 40] [Article Influence: 5.6] [Reference Citation Analysis]
9 Holbrook RJ, Rammohan N, Rotz MW, MacRenaris KW, Preslar AT, Meade TJ. Gd(III)-Dithiolane Gold Nanoparticles for T1-Weighted Magnetic Resonance Imaging of the Pancreas. Nano Lett 2016;16:3202-9. [PMID: 27050622 DOI: 10.1021/acs.nanolett.6b00599] [Cited by in Crossref: 50] [Cited by in F6Publishing: 44] [Article Influence: 10.0] [Reference Citation Analysis]
10 Beeghly-fadiel A, Luu HN, Du L, Shi C, Mcgavic DP, Parikh AA, Raskin L. Early onset pancreatic malignancies: Clinical characteristics and survival associations: Early onset pancreatic malignancies. Int J Cancer 2016;139:2169-77. [DOI: 10.1002/ijc.30273] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
11 Nicholson JA, Greenhalf W, Jackson R, Cox TF, Butler JV, Hanna T, Harrison S, Grocock CJ, Halloran CM, Howes NR, Raraty MG, Ghaneh P, Johnstone M, Sarkar S, Smart HL, Evans JC, Aithal GP, Sutton R, Neoptolemos JP, Lombard MG. Incidence of Post-ERCP Pancreatitis From Direct Pancreatic Juice Collection in Hereditary Pancreatitis and Familial Pancreatic Cancer Before and After the Introduction of Prophylactic Pancreatic Stents and Rectal Diclofenac. Pancreas 2015;44:260-5. [DOI: 10.1097/mpa.0000000000000246] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Smith AL, Bascuñana C, Hall A, Salman A, Andrei AZ, Volenik A, Rothenmund H, Ferland D, Lamoussenery D, Kamath AS, Amre R, Caglar D, Gao ZH, Haegert DG, Kanber Y, Michel RP, Omeroglu-Altinel G, Asselah J, Bouganim N, Kavan P, Arena G, Barkun J, Chaudhury P, Gallinger S, Foulkes WD, Omeroglu A, Metrakos P, Zogopoulos G. Establishing a clinic-based pancreatic cancer and periampullary tumour research registry in Quebec. Curr Oncol 2015;22:113-21. [PMID: 25908910 DOI: 10.3747/co.22.2300] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
13 Liu K, Ji B, Zhang W, Liu S, Wang Y, Liu Y. Comparison of iodine-125 seed implantation and pancreaticoduodenectomy in the treatment of pancreatic cancer. Int J Med Sci. 2014;11:893-896. [PMID: 25013369 DOI: 10.7150/ijms.8948] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
14 Forsberg F, Stanczak M, Lyshchik A, Loren D, O'Kane P, Siddiqui A, Kowalski TE, Miller C, Fox T, Liu JB, Eisenbrey JR. Subharmonic and Endoscopic Contrast Imaging of Pancreatic Masses: A Pilot Study. J Ultrasound Med 2018;37:123-9. [PMID: 28681437 DOI: 10.1002/jum.14310] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
15 Jiang L, Gu Y, Du Y, Liu J. Exosomes: Diagnostic Biomarkers and Therapeutic Delivery Vehicles for Cancer. Mol Pharm 2019;16:3333-49. [PMID: 31241965 DOI: 10.1021/acs.molpharmaceut.9b00409] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 18.5] [Reference Citation Analysis]
16 Li N, Wang C, Zhang P, You S. Emodin inhibits pancreatic cancer EMT and invasion by up‑regulating microRNA‑1271. Mol Med Rep 2018;18:3366-74. [PMID: 30066876 DOI: 10.3892/mmr.2018.9304] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
17 Karakas Y, Lacin S, Yalcin S. Recent advances in the management of pancreatic adenocarcinoma. Expert Review of Anticancer Therapy 2018;18:51-62. [DOI: 10.1080/14737140.2018.1403319] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
18 Smith AL, Alirezaie N, Connor A, Chan-Seng-Yue M, Grant R, Selander I, Bascuñana C, Borgida A, Hall A, Whelan T, Holter S, McPherson T, Cleary S, Petersen GM, Omeroglu A, Saloustros E, McPherson J, Stein LD, Foulkes WD, Majewski J, Gallinger S, Zogopoulos G. Candidate DNA repair susceptibility genes identified by exome sequencing in high-risk pancreatic cancer. Cancer Lett 2016;370:302-12. [PMID: 26546047 DOI: 10.1016/j.canlet.2015.10.030] [Cited by in Crossref: 36] [Cited by in F6Publishing: 31] [Article Influence: 6.0] [Reference Citation Analysis]
19 Ohmoto A, Yachida S, Kubo E, Takai E, Suzuki M, Shimada K, Okusaka T, Morizane C. Clinicopathologic Features and Germline Sequence Variants in Young Patients (≤40 Years Old) With Pancreatic Ductal Adenocarcinoma. Pancreas 2016;45:1056-61. [DOI: 10.1097/mpa.0000000000000574] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
20 Zhu G, Song J, Chen W, Yuan D, Wang W, Chen X, Liu H, Su H, Zhu J. Expression and Role of Dickkopf-1 (Dkk1) in Tumors: From the Cells to the Patients. Cancer Manag Res 2021;13:659-75. [PMID: 33536782 DOI: 10.2147/CMAR.S275172] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
21 Zhen DB, Rabe KG, Gallinger S, Syngal S, Schwartz AG, Goggins MG, Hruban RH, Cote ML, McWilliams RR, Roberts NJ, Cannon-Albright LA, Li D, Moyes K, Wenstrup RJ, Hartman AR, Seminara D, Klein AP, Petersen GM. BRCA1, BRCA2, PALB2, and CDKN2A mutations in familial pancreatic cancer: a PACGENE study. Genet Med. 2015;17:569-577. [PMID: 25356972 DOI: 10.1038/gim.2014.153] [Cited by in Crossref: 144] [Cited by in F6Publishing: 130] [Article Influence: 20.6] [Reference Citation Analysis]
22 Kanteti R, Batra SK, Lennon FE, Salgia R. FAK and paxillin, two potential targets in pancreatic cancer. Oncotarget 2016;7:31586-601. [PMID: 26980710 DOI: 10.18632/oncotarget.8040] [Cited by in Crossref: 54] [Cited by in F6Publishing: 50] [Article Influence: 13.5] [Reference Citation Analysis]
23 Bo X, Shi J, Liu R, Geng S, Li Q, Li Y, Jin H, Yang S, Jiang H, Wang Z. Using the Risk Factors of Pancreatic Cancer and Their Interactions in Cancer Screening: A Case-Control Study in Shanghai, China. Ann Glob Health 2019;85:103. [PMID: 31298822 DOI: 10.5334/aogh.2463] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
24 Sheel ARG, Harrison S, Sarantitis I, Nicholson JA, Hanna T, Grocock C, Raraty M, Ramesh J, Farooq A, Costello E, Jackson R, Chapman M, Smith A, Carter R, Mckay C, Hamady Z, Aithal GP, Mountford R, Ghaneh P, Hammel P, Lerch MM, Halloran C, Pereira SP, Greenhalf W. Identification of Cystic Lesions by Secondary Screening of Familial Pancreatic Cancer (FPC) Kindreds Is Not Associated with the Stratified Risk of Cancer. Am J Gastroenterol 2019;114:155-64. [PMID: 30353057 DOI: 10.1038/s41395-018-0395-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
25 Honda K, Srivastava S. Potential usefulness of apolipoprotein A2 isoforms for screening and risk stratification of pancreatic cancer. Biomark Med 2016;10:1197-207. [PMID: 27673558 DOI: 10.2217/bmm-2016-0209] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.6] [Reference Citation Analysis]
26 Ohmoto A, Morizane C, Kubo E, Takai E, Hosoi H, Sakamoto Y, Kondo S, Ueno H, Shimada K, Yachida S, Okusaka T. Germline variants in pancreatic cancer patients with a personal or family history of cancer fulfilling the revised Bethesda guidelines. J Gastroenterol 2018;53:1159-67. [PMID: 29667044 DOI: 10.1007/s00535-018-1466-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
27 Lee YE, Ju A, Choi HW, Kim JC, Kim EE, Kim TS, Kang HJ, Kim SY, Jang JY, Ku JL, Kim SC, Jun E, Jang M. Rationally designed redirection of natural killer cells anchoring a cytotoxic ligand for pancreatic cancer treatment. J Control Release. 2020;326:310-323. [PMID: 32682905 DOI: 10.1016/j.jconrel.2020.07.016] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
28 Chang DK, Grimmond SM, Biankin AV. Pancreatic cancer genomics. Curr Opin Genet Dev. 2014;24:74-81. [PMID: 24480245 DOI: 10.1016/j.gde.2013.12.001] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 4.9] [Reference Citation Analysis]
29 Wang W, Ning JZ, Tang ZG, He Y, Yao LC, Ye L, Wu L. MicroRNA-23a acts as an oncogene in pancreatic carcinoma by targeting TFPI-2. Exp Ther Med 2020;20:53. [PMID: 32952643 DOI: 10.3892/etm.2020.9181] [Reference Citation Analysis]
30 Hanada K, Okazaki A, Hirano N, Izumi Y, Minami T, Ikemoto J, Kanemitsu K, Hino F. Effective screening for early diagnosis of pancreatic cancer. Best Pract Res Clin Gastroenterol 2015;29:929-39. [PMID: 26651254 DOI: 10.1016/j.bpg.2015.09.017] [Cited by in Crossref: 31] [Cited by in F6Publishing: 23] [Article Influence: 5.2] [Reference Citation Analysis]
31 Yu Y, Tian L, Feng X, Cheng J, Gong Y, Liu X, Zhang Z, Yang X, He S, Li C, Huang Q. eIF4E-phosphorylation-mediated Sox2 upregulation promotes pancreatic tumor cell repopulation after irradiation. Cancer Letters 2016;375:31-8. [DOI: 10.1016/j.canlet.2016.02.052] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
32 Kim H, Saka B, Knight S, Borges M, Childs E, Klein A, Wolfgang C, Herman J, Adsay VN, Hruban RH, Goggins M. Having pancreatic cancer with tumoral loss of ATM and normal TP53 protein expression is associated with a poorer prognosis. Clin Cancer Res 2014;20:1865-72. [PMID: 24486587 DOI: 10.1158/1078-0432.CCR-13-1239] [Cited by in Crossref: 55] [Cited by in F6Publishing: 26] [Article Influence: 7.9] [Reference Citation Analysis]
33 Hanada K, Okazaki A, Hirano N, Izumi Y, Teraoka Y, Ikemoto J, Kanemitsu K, Hino F, Fukuda T, Yonehara S. Diagnostic strategies for early pancreatic cancer. J Gastroenterol. 2015;50:147-154. [PMID: 25501287 DOI: 10.1007/s00535-014-1026-z] [Cited by in Crossref: 59] [Cited by in F6Publishing: 49] [Article Influence: 8.4] [Reference Citation Analysis]
34 Hu C, LaDuca H, Shimelis H, Polley EC, Lilyquist J, Hart SN, Na J, Thomas A, Lee KY, Davis BT, Black MH, Pesaran T, Goldgar DE, Dolinsky JS, Couch FJ. Multigene Hereditary Cancer Panels Reveal High-Risk Pancreatic Cancer Susceptibility Genes. JCO Precis Oncol 2018;2. [PMID: 31497750 DOI: 10.1200/PO.17.00291] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
35 Yu Y, Feng X, Cang S. A two-microRNA signature as a diagnostic and prognostic marker of pancreatic adenocarcinoma. Cancer Manag Res 2018;10:1507-15. [PMID: 29942152 DOI: 10.2147/CMAR.S158712] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
36 Caldwell KE, Conway AP, Hammill CW. Screening for Pancreatic Ductal Adenocarcinoma: Are We Asking the Impossible? Cancer Prev Res (Phila) 2021;14:373-82. [PMID: 33148677 DOI: 10.1158/1940-6207.CAPR-20-0426] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
37 Ansari D, Tingstedt B, Andersson B, Holmquist F, Sturesson C, Williamsson C, Sasor A, Borg D, Bauden M, Andersson R. Pancreatic cancer: yesterday, today and tomorrow. Future Oncol. 2016;12:1929-1946. [PMID: 27246628 DOI: 10.2217/fon-2016-0010] [Cited by in Crossref: 106] [Cited by in F6Publishing: 104] [Article Influence: 21.2] [Reference Citation Analysis]
38 Zhang Q, Zeng L, Chen Y, Lian G, Qian C, Chen S, Li J, Huang K. Pancreatic Cancer Epidemiology, Detection, and Management. Gastroenterol Res Pract 2016;2016:8962321. [PMID: 26941789 DOI: 10.1155/2016/8962321] [Cited by in Crossref: 61] [Cited by in F6Publishing: 69] [Article Influence: 12.2] [Reference Citation Analysis]
39 Li W, Wang X, Wang Z, Zhang T, Cai F, Tang P, Meng J, Du H, Wang H, Li M, Li S. The role of seed implantation in patients with unresectable pancreatic carcinoma after relief of obstructive jaundice using ERCP. Brachytherapy 2020;19:97-103. [PMID: 31564517 DOI: 10.1016/j.brachy.2019.08.010] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
40 Nanda N, Roberts NJ. ATM Serine/Threonine Kinase and its Role in Pancreatic Risk. Genes (Basel) 2020;11:E108. [PMID: 31963441 DOI: 10.3390/genes11010108] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
41 Hall M, Liu H, Malafa M, Centeno B, Hodul PJ, Pimiento J, Pilon-Thomas S, Sarnaik AA. Expansion of tumor-infiltrating lymphocytes (TIL) from human pancreatic tumors. J Immunother Cancer 2016;4:61. [PMID: 27777771 DOI: 10.1186/s40425-016-0164-7] [Cited by in Crossref: 47] [Cited by in F6Publishing: 45] [Article Influence: 9.4] [Reference Citation Analysis]
42 Rustgi AK. Familial pancreatic cancer: genetic advances. Genes Dev. 2014;28:1-7. [PMID: 24395243 DOI: 10.1101/gad.228452.113] [Cited by in Crossref: 62] [Cited by in F6Publishing: 56] [Article Influence: 8.9] [Reference Citation Analysis]
43 Zhang Z, Chen H, Lu Y, Feng T, Sun W. LncRNA BC032020 suppresses the survival of human pancreatic ductal adenocarcinoma cells by targeting ZNF451. Int J Oncol 2018;52:1224-34. [PMID: 29532883 DOI: 10.3892/ijo.2018.4289] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
44 Niu H, Zhang X, Wang B, Zhou Z, Wang J, Xu Z. The clinical utility of image-guided iodine-125 seed in patients with unresectable pancreatic cancer. Tumour Biol. 2016;37:2219-2223. [PMID: 26353858 DOI: 10.1007/s13277-015-4045-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
45 Chen H, Hou GY, Han Y, Payen T, Palermo CF, Olive KP, Konofagou EE. Harmonic motion imaging for abdominal tumor detection and high-intensity focused ultrasound ablation monitoring: an in vivo feasibility study in a transgenic mouse model of pancreatic cancer. IEEE Trans Ultrason Ferroelectr Freq Control 2015;62:1662-73. [PMID: 26415128 DOI: 10.1109/TUFFC.2015.007113] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
46 Löhr JM, Haas SL, Kröger JC, Friess HM, Höft R, Goretzki PE, Peschel C, Schweigert M, Salmons B, Gunzburg WH. Encapsulated cells expressing a chemotherapeutic activating enzyme allow the targeting of subtoxic chemotherapy and are safe and efficacious: data from two clinical trials in pancreatic cancer. Pharmaceutics. 2014;6:447-466. [PMID: 25116885 DOI: 10.3390/pharmaceutics6030447] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
47 Candido S, Abrams SL, Steelman LS, Lertpiriyapong K, Martelli AM, Cocco L, Ratti S, Follo MY, Murata RM, Rosalen PL, Bueno-silva B, de Alencar SM, Lombardi P, Mao W, Montalto G, Cervello M, Rakus D, Gizak A, Lin H, Libra M, Akula SM, Mccubrey JA. Effects of the MDM-2 inhibitor Nutlin-3a on PDAC cells containing and lacking WT-TP53 on sensitivity to chemotherapy, signal transduction inhibitors and nutraceuticals. Advances in Biological Regulation 2019;72:22-40. [DOI: 10.1016/j.jbior.2019.03.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
48 Kalyane D, Choudhary D, Polaka S, Goykar H, Anup N, Tambe V, Kalia K, Tekade RK. Exosomes in multidrug-resistant cancer. Current Opinion in Pharmacology 2020;54:109-20. [DOI: 10.1016/j.coph.2020.08.017] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
49 Neuzillet C, Tijeras-Raballand A, Bourget P, Cros J, Couvelard A, Sauvanet A, Vullierme MP, Tournigand C, Hammel P. State of the art and future directions of pancreatic ductal adenocarcinoma therapy. Pharmacol Ther. 2015;155:80-104. [PMID: 26299994 DOI: 10.1016/j.pharmthera.2015.08.006] [Cited by in Crossref: 58] [Cited by in F6Publishing: 57] [Article Influence: 9.7] [Reference Citation Analysis]
50 Shindo K, Yu J, Suenaga M, Fesharakizadeh S, Cho C, Macgregor-Das A, Siddiqui A, Witmer PD, Tamura K, Song TJ, Navarro Almario JA, Brant A, Borges M, Ford M, Barkley T, He J, Weiss MJ, Wolfgang CL, Roberts NJ, Hruban RH, Klein AP, Goggins M. Deleterious Germline Mutations in Patients With Apparently Sporadic Pancreatic Adenocarcinoma. J Clin Oncol 2017;35:3382-90. [PMID: 28767289 DOI: 10.1200/JCO.2017.72.3502] [Cited by in Crossref: 167] [Cited by in F6Publishing: 100] [Article Influence: 41.8] [Reference Citation Analysis]
51 Sakai T, Mashima H, Yamada Y, Goto T, Sato W, Dohmen T, Kamada K, Yoshioka M, Uchinami H, Yamamoto Y, Ohnishi H. The roles of interferon regulatory factors 1 and 2 in the progression of human pancreatic cancer. Pancreas 2014;43:909-16. [PMID: 24632547 DOI: 10.1097/MPA.0000000000000116] [Cited by in Crossref: 25] [Cited by in F6Publishing: 15] [Article Influence: 4.2] [Reference Citation Analysis]
52 Harpstrite SE, Gu H, Natarajan R, Sharma V. Interrogation of multidrug resistance (MDR1) P-glycoprotein (ABCB1) expression in human pancreatic carcinoma cells: correlation of 99mTc-Sestamibi uptake with western blot analysis. Nucl Med Commun 2014;35:1067-70. [PMID: 25036383 DOI: 10.1097/MNM.0000000000000158] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 2.2] [Reference Citation Analysis]
53 Kurtanich T, Roos N, Wang G, Yang J, Wang A, Chung EJ. Pancreatic Cancer Gene Therapy Delivered by Nanoparticles. SLAS Technol. 2019;24:151-160. [PMID: 30395768 DOI: 10.1177/2472630318811108] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
54 Catts ZA, Baig MK, Milewski B, Keywan C, Guarino M, Petrelli N. Statewide Retrospective Review of Familial Pancreatic Cancer in Delaware, and Frequency of Genetic Mutations in Pancreatic Cancer Kindreds. Ann Surg Oncol 2016;23:1729-35. [DOI: 10.1245/s10434-015-5026-x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
55 Yu J, Blackford AL, Dal Molin M, Wolfgang CL, Goggins M. Time to progression of pancreatic ductal adenocarcinoma from low-to-high tumour stages. Gut. 2015;Epub ahead of print. [PMID: 25636698 DOI: 10.1136/gutjnl-2014-308653] [Cited by in Crossref: 84] [Cited by in F6Publishing: 92] [Article Influence: 14.0] [Reference Citation Analysis]
56 Xia Y, Lei Q, Zhu Y, Ye T, Wang N, Li G, Shi X, Liu Y, Shao B, Yin T, Zhao L, Wu W, Song X, Xiong Y, Wei Y, Yu L. SKLB316, a novel small-molecule inhibitor of cell-cycle progression, induces G2/M phase arrest and apoptosis in vitro and inhibits tumor growth in vivo. Cancer Lett 2014;355:297-309. [PMID: 25301449 DOI: 10.1016/j.canlet.2014.09.042] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 3.7] [Reference Citation Analysis]
57 Hanada K, Amano H, Abe T. Early diagnosis of pancreatic cancer: Current trends and concerns. Ann Gastroenterol Surg 2017;1:44-51. [PMID: 29863166 DOI: 10.1002/ags3.12004] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
58 Abrams SL, Lertpiriyapong K, Yang LV, Martelli AM, Cocco L, Ratti S, Falasca M, Murata RM, Rosalen PL, Lombardi P, Libra M, Candido S, Montalto G, Cervello M, Steelman LS, Mccubrey JA. Introduction of WT-TP53 into pancreatic cancer cells alters sensitivity to chemotherapeutic drugs, targeted therapeutics and nutraceuticals. Advances in Biological Regulation 2018;69:16-34. [DOI: 10.1016/j.jbior.2018.06.002] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
59 Shindo K, Yu J, Suenaga M, Fesharakizadeh S, Tamura K, Almario JAN, Brant A, Borges M, Siddiqui A, Datta L, Wolfgang CL, Hruban RH, Klein AP, Goggins M. Lack of association between the pancreatitis risk allele CEL-HYB and pancreatic cancer. Oncotarget 2017;8:50824-31. [PMID: 28881607 DOI: 10.18632/oncotarget.15137] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
60 Joergensen MT, Gerdes AM, Sorensen J, Schaffalitzky de Muckadell O, Mortensen MB. Is screening for pancreatic cancer in high-risk groups cost-effective? - Experience from a Danish national screening program. Pancreatology 2016;16:584-92. [PMID: 27090585 DOI: 10.1016/j.pan.2016.03.013] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 4.8] [Reference Citation Analysis]
61 Rahimi E, Batra S, Thosani N, Singh H, Guha S. Increased Incidence of Second Primary Pancreatic Cancer in Patients with Prior Colorectal Cancer: A Population-Based US Study. Dig Dis Sci 2016;61:1652-60. [PMID: 27107866 DOI: 10.1007/s10620-016-4170-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
62 Chen F, Roberts NJ, Klein AP. Inherited pancreatic cancer. Chin Clin Oncol. 2017;6:58. [PMID: 29307198 DOI: 10.21037/cco.2017.12.04] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
63 Ghiorzo P. Genetic predisposition to pancreatic cancer. World J Gastroenterol 2014; 20(31): 10778-10789 [PMID: 25152581 DOI: 10.3748/wjg.v20.i31.10778] [Cited by in CrossRef: 49] [Cited by in F6Publishing: 44] [Article Influence: 7.0] [Reference Citation Analysis]
64 Nahire R, Hossain R, Patel R, Paul S, Meghnani V, Ambre AH, Gange KN, Katti KS, Leclerc E, Srivastava DK, Sarkar K, Mallik S. pH-triggered echogenicity and contents release from liposomes. Mol Pharm 2014;11:4059-68. [PMID: 25271780 DOI: 10.1021/mp500186a] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.9] [Reference Citation Analysis]
65 Hu C, Hart SN, Bamlet WR, Moore RM, Nandakumar K, Eckloff BW, Lee YK, Petersen GM, McWilliams RR, Couch FJ. Prevalence of Pathogenic Mutations in Cancer Predisposition Genes among Pancreatic Cancer Patients. Cancer Epidemiol Biomarkers Prev 2016;25:207-11. [PMID: 26483394 DOI: 10.1158/1055-9965.EPI-15-0455] [Cited by in Crossref: 81] [Cited by in F6Publishing: 43] [Article Influence: 13.5] [Reference Citation Analysis]
66 Tomita Y, Azuma K, Nonaka Y, Kamada Y, Tomoeda M, Kishida M, Tanemura M, Miyoshi E. Pancreatic fatty degeneration and fibrosis as predisposing factors for the development of pancreatic ductal adenocarcinoma. Pancreas. 2014;43:1032-1041. [PMID: 24991971 DOI: 10.1097/mpa.0000000000000159] [Cited by in Crossref: 35] [Cited by in F6Publishing: 18] [Article Influence: 5.8] [Reference Citation Analysis]
67 Castle J, Kotopoulis S, Forsberg F. Sonoporation for Augmenting Chemotherapy of Pancreatic Ductal Adenocarcinoma. Methods Mol Biol 2020;2059:191-205. [PMID: 31435922 DOI: 10.1007/978-1-4939-9798-5_9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
68 You X, Zhu D, Lu W, Sun Y, Qiao S, Luo B, Du Y, Pi R, Hu Y, Huang P, Wen S. Design, synthesis and biological evaluation of N -arylsulfonyl carbazoles as novel anticancer agents. RSC Adv 2018;8:17183-90. [DOI: 10.1039/c8ra02939c] [Cited by in Crossref: 10] [Article Influence: 3.3] [Reference Citation Analysis]
69 Takeuchi S, Doi M, Ikari N, Yamamoto M, Furukawa T. Mutations in BRCA1, BRCA2, and PALB2, and a panel of 50 cancer-associated genes in pancreatic ductal adenocarcinoma. Sci Rep 2018;8:8105. [PMID: 29802286 DOI: 10.1038/s41598-018-26526-x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 6.0] [Reference Citation Analysis]
70 Hsu FC, Roberts NJ, Childs E, Porter N, Rabe KG, Borgida A, Ukaegbu C, Goggins MG, Hruban RH, Zogopoulos G, Syngal S, Gallinger S, Petersen GM, Klein AP. Risk of Pancreatic Cancer Among Individuals With Pathogenic Variants in the ATM Gene. JAMA Oncol 2021. [PMID: 34529012 DOI: 10.1001/jamaoncol.2021.3701] [Reference Citation Analysis]
71 Yuan W, Yang D, Su Q, Zhu X, Cao T, Sun Y, Dai Y, Feng W, Li F. Intraperitoneal Administration of Biointerface-Camouflaged Upconversion Nanoparticles for Contrast Enhanced Imaging of Pancreatic Cancer. Adv Funct Mater 2016;26:8631-42. [DOI: 10.1002/adfm.201603907] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 3.2] [Reference Citation Analysis]
72 Shin J, Kim D, Kim HL, Choi M, Koh Y, Yoon SS. Oncogenic effects of germline variants in lysosomal storage disease genes. Genet Med 2019;21:2695-705. [PMID: 31341245 DOI: 10.1038/s41436-019-0588-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
73 Humphris JL, Biankin AV. Diagnosis and Management of Hereditary Pancreatic Cancer. In: Pichert G, Jacobs C, editors. Rare Hereditary Cancers. Cham: Springer International Publishing; 2016. pp. 61-83. [DOI: 10.1007/978-3-319-29998-3_5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
74 Kuhlmann L, Nadler WM, Kerner A, Hanke SA, Noll EM, Eisen C, Espinet E, Vogel V, Trumpp A, Sprick MR, Roesli CP. Identification and Validation of Novel Subtype-Specific Protein Biomarkers in Pancreatic Ductal Adenocarcinoma. Pancreas 2017;46:311-22. [DOI: 10.1097/mpa.0000000000000743] [Cited by in Crossref: 18] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
75 Han F, Xu Q, Zhao J, Xiong P, Liu J. ERO1L promotes pancreatic cancer cell progression through activating the Wnt/catenin pathway. J Cell Biochem 2018;119:8996-9005. [PMID: 30076651 DOI: 10.1002/jcb.27155] [Cited by in Crossref: 9] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
76 Hata T, Mizuma M, Motoi F, Ishida M, Ohtsuka H, Nakagawa K, Morikawa T, Furukawa T, Unno M. Germline DNA damage repair gene mutations in pancreatic cancer patients with personal/family histories of pancreas/breast/ovarian/prostate cancer in a Japanese population. Ann Gastroenterol Surg 2021;5:853-64. [PMID: 34755017 DOI: 10.1002/ags3.12482] [Reference Citation Analysis]
77 Abrams SL, Akula SM, Martelli AM, Cocco L, Ratti S, Libra M, Candido S, Montalto G, Cervello M, Gizak A, Rakus D, Steelman LS, McCubrey JA. Sensitivity of pancreatic cancer cells to chemotherapeutic drugs, signal transduction inhibitors and nutraceuticals can be regulated by WT-TP53. Adv Biol Regul 2021;79:100780. [PMID: 33451973 DOI: 10.1016/j.jbior.2020.100780] [Reference Citation Analysis]
78 Bruenderman EH, Martin RC 2nd. High-risk population in sporadic pancreatic adenocarcinoma: guidelines for screening. J Surg Res. 2015;194:212-219. [PMID: 25479908 DOI: 10.1016/j.jss.2014.06.046] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 2.1] [Reference Citation Analysis]
79 Das KK, Early D. Pancreatic cancer screening. Curr Treat Options Gastroenterol. 2017;15:562-575. [PMID: 28879469 DOI: 10.1007/s11938-017-0149-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
80 Wong C, Chen F, Alirezaie N, Wang Y, Cuggia A, Borgida A, Holter S, Lenko T, Domecq C, Petersen GM, Syngal S, Brand R, Rustgi AK, Cote ML, Stoffel E, Olson SH, Roberts NJ, Akbari MR, Majewski J, Klein AP, Greenwood CMT, Gallinger S, Zogopoulos G; Alzheimer’s Disease Neuroimaging Initiative. A region-based gene association study combined with a leave-one-out sensitivity analysis identifies SMG1 as a pancreatic cancer susceptibility gene. PLoS Genet 2019;15:e1008344. [PMID: 31469826 DOI: 10.1371/journal.pgen.1008344] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
81 Humphris J, Chang DK, Biankin AV. Inherited Susceptibility to Pancreatic Cancer in the Era of Next-Generation Sequencing. Gastroenterology 2015;148:496-8. [DOI: 10.1053/j.gastro.2015.01.009] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
82 Kanji ZS, Gallinger S. Diagnosis and management of pancreatic cancer. CMAJ. 2013;185:1219-1226. [PMID: 23610017 DOI: 10.1503/cmaj.121368] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 2.9] [Reference Citation Analysis]